Florou Vaia, Wilky Breelyn A
Department of Internal Medicine, Division of Oncology, Huntsman Cancer Institute, University of Utah School of Medicine, 2000 Circle of Hope, Salt Lake City, UT, USA.
Department of Medicine, Division of Medical Oncology, University of Colorado School of Medicine, 1665 Aurora Court Anschutz Cancer Pavilion, Aurora, CO, USA.
Curr Treat Options Oncol. 2021 Jun 7;22(7):61. doi: 10.1007/s11864-021-00858-9.
Despite their rarity, angiosarcomas are one of the most aggressive soft tissue sarcomas. Management can often be challenging due to their location and infiltrative nature. A multidisciplinary treatment approach is always warranted, but the recurrence remains high even for localized tumors despite multimodality treatment. In the metastatic setting, cytotoxic chemotherapies, targeted therapies, and, more recently, immunotherapy are used. The sequence of systemic therapies remains currently a topic of active investigation. Over the last couple of years, there have been significant advances in understanding angiosarcoma biology, most notably via patient-driven initiatives like the Angiosarcoma Project. The knowledge derived from such translational work has led to identifying potential biomarkers of response to treatments and exploring new therapeutic avenues. More clinical trials are underway to expand treatment options and improve patient outcomes.
尽管血管肉瘤罕见，但却是最具侵袭性的软组织肉瘤之一。由于其位置和浸润性，治疗往往具有挑战性。多学科治疗方法始终是必要的，但即使是局部肿瘤，尽管采用了多模式治疗，复发率仍然很高。在转移的情况下，会使用细胞毒性化疗、靶向治疗，以及最近的免疫治疗。全身治疗的顺序目前仍是一个积极研究的课题。在过去几年里，在理解血管肉瘤生物学方面取得了重大进展，最显著的是通过像血管肉瘤项目这样由患者推动的倡议。从这种转化性工作中获得的知识已导致识别出对治疗有反应的潜在生物标志物，并探索新的治疗途径。正在进行更多的临床试验以扩大治疗选择并改善患者预后。
